Cassiopea Partners acted as financial advisor to Named Group, the Italian market leader in dietary supplements, medical devices, and cosmetics, in the acquisition of 100% of the share capital of New Penta, a leading Italian integrated nutrition player, from Orienta Capital Partners and Mr. Guido Dracone.
New Penta provides services and products, grounded in ongoing scientific research, to nutritionists and other healthcare providers to improve the mental and physical health of their patients. Doctors and nutritionists use the method developed by New Penta with a variety of goals, including controlling patients’ weight and managing intolerances or chronic diseases (e.g., diabetes). Headquartered in Castelletto Stura (Cuneo, Italy), New Penta has innovatively supported more than 2,000 dietitian nutritionists, working alongside them in caring for more than 150,000 patients.
New Penta’s entry into Named Group allows both entities to leverage important commercial synergies, for example on specialized sales representatives’ networks and on a complementary product portfolio. In addition, New Penta will be able to provide its network with direct access to Named Group products, such as the innovative WellMicro gut microbiota test, which provides targeted and personalized recommendations to patients.
The selling shareholders Orienta Capital Partners and Guido Dracone, who retains the position of CEO of New Penta, have reinvested in Named Group.
Named Group, controlled by White Bridge Investments, is Italy’s first nutraceutical hub, born from the union of Specchiasol, Named, Phyto Garda, Wellmicro, Farma-Derma, Named sport and GDI Martera. The result is a concentration of expertise aimed at ensuring wellness and maintaining health through scientific studies and the enhancement of what nature has to offer. The Group develops new analytical tools to support professionals and consumers, as well as innovative portfolios of nutraceuticals that precisely and individually address the needs of those who rely on natural supplements. Named Group in 2022 will reach approx. €170m revenues with more than 500 employees.
Alessio Romitelli, Chief Operating Officer of Named Group, explains, “The transaction with New Penta will further strengthen Named Group’s leadership position in the Italian nutraceutical market. The synergies that can be generated between the various companies in the group are significant and capable of developing further growth paths for both New Penta and the rest of the group.”
With this transaction, Cassiopea Partners further highlights its experience in the healthcare and nutraceutical sector and its ability to facilitate inorganic growth strategies for its clients.
Alongside Cassiopea Partners, Named Group was assisted by Giovannelli e Associati for the legal aspects and by Deloitte for the financial and tax due diligence.
